Genmab — Juni 2024
-
TECVAYLI
(teclistamab-cqyv) shows sustained deep and durable responses in patients with relapsed or refractory multiple myeloma https://www.jnj.com/media-center/press-releases/tecvayli-teclistamab-cqyv-shows-sustained-deep-and-durable-responses-in-patients-with-relapsed-or-refractory-multiple-myeloma#:~:text=CHICAGO (June 3%2C 2024),and who previously received three -
Tillykke Monforte, håber det fortsætter på samme vis
-
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
-
-
@gdn55 kl. 14.13.... Er enig, hvis kursen er nuværende eller under og data er gode på Superdara. Så køber de højest sandsynligt biksen..... Men med det du skriver, siger du egentlig også mellem linjerne at det er JnJ der styrer kursen.... - Den tror jeg ikke på...
-
Genmab melder om opmuntrende forsøgsdata fra kræftmiddel https://proinvestor.com/investornyt/1167992/genmab-melder-om-opmuntrende-forsogsdata-fra-kraeftmiddel
-
June 3, 2024 4:00 PM CEST : Virtual mid- to late-stage pipeline update at ASCO 2024 https://proinvestor.com/investornyt/1167993/june-3-2024-400-pm-cest-virtual-mid-to-late-stage-pipeline-update-at-asco-2024
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind